📄 infectious diseases
More Shots on Goal: Heterologous Influenza Prime-Boost Vaccination Decreases the Likelihood of a Negligible Antibody Response to Current or Historical Variants
This phase 4 clinical trial demonstrates that a heterologous prime-boost influenza vaccination strategy effectively halts antibody waning and significantly reduces the rate of non-responders to current and historical strains compared to single-dose or homologous boosting, likely by overcoming immune imprinting limitations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.